Fennec Pharmaceuticals. has been granted a patent for anhydrous sodium thiosulfate, detailing its synthesis and pharmaceutical formulations. The compositions aim to reduce ototoxicity in pediatric patients undergoing platinum-based chemotherapy, with a specific method involving a 0.5 M concentration of the compound combined with boric acid. GlobalData’s report on Fennec Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Fennec Pharmaceuticals, Nanoparticle drug conjugates was a key innovation area identified from patents. Fennec Pharmaceuticals's grant share as of June 2024 was 35%. Grant share is based on the ratio of number of grants to total number of patents.
Reducing ototoxicity in patients receiving platinum-based chemotherapy
The patent US11998604B2 outlines a method aimed at reducing ototoxicity in human patients undergoing treatment with platinum-based chemotherapeutics, specifically cisplatin, for various cancers. The method involves administering a pharmaceutical composition that includes aqueous anhydrous sodium thiosulfate at a concentration of approximately 0.5 M, along with about 0.004 M boric acid. Additional components may include hydrochloric acid and sodium hydroxide, with the composition's pH maintained between 5 and 9.5, and more specifically between 6.5 and 8.9 or 8.6 and 8.8. The method is particularly applicable to pediatric patients, including those five years of age or younger, who may be diagnosed with conditions such as hepatoblastoma, medulloblastoma, neuroblastoma, osteosarcoma, localized cancer, disseminated cancer, or germ cell tumors.
The administration of cisplatin is typically performed as an infusion over a period of 1 to 6 hours, with the sodium thiosulfate composition given approximately 6 hours post-infusion. This subsequent administration is designed to mitigate the ototoxic effects associated with cisplatin treatment. The claims also specify that the pharmaceutical composition can be infused over about 15 minutes, ensuring a timely intervention to protect against potential hearing loss in patients receiving this chemotherapy. The patent thus presents a targeted approach to enhance the safety profile of cisplatin therapy in vulnerable pediatric populations.
To know more about GlobalData’s detailed insights on Fennec Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
